Tunn U: The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int. 2007, 99 (Suppl 1): 19-22. discussion 3-4
Article
CAS
PubMed
Google Scholar
National Cancer Institute: Prostate Cancer Treatment (PDQ®). General Information About Prostate Cancer. http://www.cancer.gov/cancertopics/pdq/treatment/prostate. Accessed on 16 December 2013
Choong K, Basaria S: Emerging cardiometabolic complications of androgen deprivation therapy. Aging Male. 2010, 13 (1): 1-9. 10.3109/13685530903410625.
Article
CAS
PubMed
Google Scholar
Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S: Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol. 2006, 4 (9): 687-696.
PubMed
Google Scholar
Abrahamsson PA: Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010, 57 (1): 49-59. 10.1016/j.eururo.2009.07.049.
Article
CAS
PubMed
Google Scholar
Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, et al: International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int. 2007, 99 (5): 1056-1065. 10.1111/j.1464-410X.2007.06770.x.
Article
CAS
PubMed
Google Scholar
National Institute for Health and Clinical Excellence: Prostate cancer: diagnosis and treatment. February 2008. http://publications.nice.org.uk/prostate-cancer-cg58/guidance#metastatic-prostate-cancer. Accessed on 16 December 2013
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al: Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013, 368 (14): 1314-1325. 10.1056/NEJMoa1212299.
Article
CAS
PubMed
PubMed Central
Google Scholar
Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al: Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012, 367 (10): 895-903. 10.1056/NEJMoa1201546.
Article
CAS
PubMed
PubMed Central
Google Scholar
Klotz L, O’ Callaghan CJ, Ding K, Dearnaley DP, Higano CS, Horwitz EM, et al: A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol. 2011, 2011: 4514-ASCO Annual Meeting Abstracts Vol 29, No 15_suppl (May 20 Supplement)
Google Scholar
Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL: The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol. 2012, 187 (6): 2074-2081. 10.1016/j.juro.2012.01.122.
Article
CAS
PubMed
Google Scholar
Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL: Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. Eur Urol. 2013, 63 (1): 111-120. 10.1016/j.eururo.2012.07.040.
Article
CAS
PubMed
Google Scholar
Dickersin K, Scherer R, Lefebvre C: Identifying relevant studies for systematic reviews. BMJ. 1994, 309 (6964): 1286-1291. 10.1136/bmj.309.6964.1286.
Article
CAS
PubMed
PubMed Central
Google Scholar
Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006. 2006, Chichester, UK: John Wiley & Sons, Ltd
Google Scholar
Castro AA, Clark OA, Atallah AN: Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J. 1999, 117 (3): 138-139.
Article
CAS
PubMed
Google Scholar
Egger M, Smith GD, Altman D: Systematic Reviews in Health Care. 2001, London: BMJ Books
Book
Google Scholar
Review Manager (RevMan): [Computer program]. Version 5.1. 2011, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration
Google Scholar
Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998, 17 (24): 2815-2834. 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8.
Article
CAS
PubMed
Google Scholar
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003, 327 (7414): 557-560. 10.1136/bmj.327.7414.557.
Article
PubMed
PubMed Central
Google Scholar
Yang K, Wang YJ, Chen XR, Chen HN: Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010, 30 (4): 229-241. 10.2165/11532260-000000000-00000.
Article
CAS
PubMed
Google Scholar
Deeks JJHJ, Altman DG: Analysing and presenting results. Cochrane Handbook for Systematic Reviews of In- terventions (ed 4.2.6 [updated September 2006]). Edited by: Higgins JP, Green S. 2006, Chichester, United Kingdom: John Wiley & Sons, Ltd
Google Scholar
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7 (3): 177-188. 10.1016/0197-2456(86)90046-2.
Article
CAS
PubMed
Google Scholar
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315 (7109): 629-634. 10.1136/bmj.315.7109.629.
Article
CAS
PubMed
PubMed Central
Google Scholar
McQuay HJ, Moore RA: Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997, 126 (9): 712-720. 10.7326/0003-4819-126-9-199705010-00007.
Article
CAS
PubMed
Google Scholar
Smeeth L, Haines A, Ebrahim S: Numbers needed to treat derived from meta-analyses–sometimes informative, usually misleading. BMJ. 1999, 318 (7197): 1548-1551. 10.1136/bmj.318.7197.1548.
Article
CAS
PubMed
PubMed Central
Google Scholar
Altman DG, Deeks JJ: Meta-analysis, Simpson’s paradox, and the number needed to treat. BMC Med Res Methodol. 2002, 2: 3-10.1186/1471-2288-2-3.
Article
PubMed
PubMed Central
Google Scholar
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009, 151 (4): W65-W94.
Article
PubMed
Google Scholar
Klotz LH, Herr HW, Morse MJ, Whitmore WF: Intermittent endocrine therapy for advanced prostate cancer. Cancer. 1986, 58 (11): 2546-2550. 10.1002/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N.
Article
CAS
PubMed
Google Scholar
Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995, 45 (5): 839-844. 10.1016/S0090-4295(99)80092-2. discussion 44-5
Article
CAS
PubMed
Google Scholar
Higano CS, Ellis W, Russell K, Lange PH: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology. 1996, 48 (5): 800-804. 10.1016/S0090-4295(96)00381-0.
Article
CAS
PubMed
Google Scholar
Oliver RT, Williams G, Paris AM, Blandy JP: Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology. 1997, 49 (1): 79-82. 10.1016/S0090-4295(96)00373-1.
Article
CAS
PubMed
Google Scholar
Bierkens AF, Hendrikx AJ, De La Rosette JJ, Stultiens GN, Beerlage HP, Arends AJ, et al: Treatment of mid- and lower ureteric calculi: extracorporeal shock-wave lithotripsy vs laser ureteroscopy. A comparison of costs, morbidity and effectiveness. Br J Urol. 1998, 81 (1): 31-35. 10.1046/j.1464-410x.1998.00510.x.
Article
CAS
PubMed
Google Scholar
Grossfeld GD, Small EJ, Carroll PR: Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. 1998, 51 (1): 137-144. 10.1016/S0090-4295(97)00488-3.
Article
CAS
PubMed
Google Scholar
da Silva Jr F C, Calais Da Silva F, Brausi M, Goncalves F, Kliment J, Queimadelos A: Pooled Analysis of two protocols of intermittent hormonal therapy in advanced prostatic cancer. : AUA 2013 Annual Meeting, 777-
De Conti P, Atallah Alvaro N, Arruda Homero O, Soares Bernardo GO, El Dib Regina P, Wilt Timothy J: Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev. 2007, Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005009.pub2/abstract, 4
Book
Google Scholar
Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007, 25 (12): 1596-1605. 10.1200/JCO.2006.10.1949.
Article
CAS
PubMed
Google Scholar
Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al: EAU guidelines on prostate cancer. Eur Urol. 2008, 53 (1): 68-80. 10.1016/j.eururo.2007.09.002.
Article
PubMed
Google Scholar
Heidenreich A, Pfister D, Ohlmann CH, Engelmann UH: Androgen deprivation for advanced prostate cancer. Urologe A. 2008, 47 (3): 270-283. 10.1007/s00120-008-1636-2.
Article
CAS
PubMed
Google Scholar
Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al: EAU guidelines on prostate cancer. Actas Urol Esp. 2009, 33 (2): 113-126. 10.1016/S0210-4806(09)74110-5.
Article
PubMed
Google Scholar
Buchan NC, Goldenberg SL: Intermittent versus continuous androgen suppression therapy: do we have consensus yet?. Curr Oncol. 2010, 17 (Suppl 2): S45-S48.
PubMed
PubMed Central
Google Scholar
Keizman D, Carducci MA: Intermittent androgen deprivation–questions remain. Nat Rev Urol. 2009, 6 (8): 412-414. 10.1038/nrurol.2009.145.
Article
PubMed
Google Scholar
Gruca D, Bacher P, Tunn U: Safety and tolerability of intermittent androgen deprivation therapy: a literature review. Int J Urol. 2012, 19 (7): 614-625. 10.1111/j.1442-2042.2012.03001.x.
Article
CAS
PubMed
Google Scholar
Organ M, Wood L, Wilke D, Skedgel C, Cheng T, North S, et al: Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial. Am J Clin Oncol. 2013, 36 (6): 601-605. 10.1097/COC.0b013e31825d5664.
Article
PubMed
Google Scholar
da Silva FE C, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, et al: Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009, 55 (6): 1269-1277. 10.1016/j.eururo.2009.02.016.
Article
Google Scholar
da Silva FM C, da SIlva F C, Bono A, Whelan P, Brausi M, Queimadelos A, et al: Phase III study of intermittent MAB vs continuos MAB. J Urol. 2011, 185 (4): e288-April 2011, AUA 2011 abstract 716
Article
Google Scholar
Tunn U, Kurek R, Keinle E, et al: Intermittent is as effective as continuous androgen deprivation in patients with PSA relapse after radical prostatectomy. J Urol. 2004, 171: 384-10.1097/01.ju.0000102933.25905.08. Abstract 1458
Article
Google Scholar
Tunn UW, Canepa G, Kochanowsky A, Kienle E: Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2012, 15 (3): 296-302. 10.1038/pcan.2012.12.
Article
CAS
PubMed
Google Scholar
Verhagen PCMS, Wissenburg LD, Wildhagen MF, et al: Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer [abstract 541]. 2008, Milan, Italy: Presented at: 23rd Annual Congress of the European Association of Urology; March 26–29, 2008
Google Scholar
Verhagen PCMS, Wildhagen MF, Verkerk A, Bolle WABM, et al: Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: Results of a randomized trial. Eur Urol. 2013, 12: e680-10.1016/S1569-9056(13)61162-8.
Article
Google Scholar
Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM: Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int. 2012, 110 (9): 1262-1269. 10.1111/j.1464-410X.2012.11120.x.
Article
CAS
PubMed
Google Scholar
de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, et al: Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer. 2002, 1 (3): 163-171. 10.3816/CGC.2002.n.018.
Article
CAS
PubMed
Google Scholar
Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF: Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol. 2011, 9:
Google Scholar
Langenhuijsen JF, Schasfoort EMC, Heathcote P, et al: Intermittent androgen suppression in patients with advanced prostate cancer: an update of the TULP survival data [abstract 538]. 2008, Milan, Italy: Presented at: 23rd Annual Congress of the European Association of Urology; March 26–29, 2008
Google Scholar
Hering F, Rodrigues PRT, Lipay MA, Nesrallah L, Srougi M: Metastatic adenocarcinoma of the prostate: comparison between continuous and intermittent hormonal treatment. Braz J Urol. 2000, 26: 276-282.
Google Scholar
Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006, 24 (24): 3984-3990. 10.1200/JCO.2006.06.4246.
Article
PubMed
Google Scholar
Miller K, Steiner U, Lingnau A, et al: Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5105]. 2007, Chicago, IL, USA: Presented at: American Society of Clinical Oncology; June 1–5
Google Scholar
Irani J, Celhay O, Hubert J, Bladou F, Ragni E, Trape G, et al: Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol. 2008, 54 (2): 382-391. 10.1016/j.eururo.2008.02.024.
Article
PubMed
Google Scholar
Silva FC, Silva FM, Goncalves F, Santos A, Kliment J, Whelan P, et al: Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the south European uroncological group. Eur Urol. 2013
Google Scholar
Prostate cancer: Guideline for the management of clinically localized prostate cancer. 2007, update. American Urological Association. Web site. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/proscan07/content.pdf
Google Scholar
Heidenreich A, Bastian PJ, Bellmunt J: Guidelines on prostate cancer. Eur Association Urol. Web site http://wwwuroweborg/gls/pdf/08ProstateCancer_LRMarch13th2012pdf
Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, et al: Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol. 2013, 64 (5): 722-730. 10.1016/j.eururo.2013.04.020.
Article
PubMed
Google Scholar
Niraula S, Le LW, Tannock IF: Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol. 2013, 31 (16): 2029-2036. 10.1200/JCO.2012.46.5492.
Article
CAS
PubMed
Google Scholar
Tsai HT, Penson DF, Makambi KH, Lynch JH, Van Den Eeden SK, Potosky AL: Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology. 2013, 82 (2): 327-334. 10.1016/j.urology.2013.01.078.
Article
PubMed
PubMed Central
Google Scholar
De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, et al: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008, 26 (1): 44-53. 10.1200/JCO.2007.11.3787.
Article
CAS
PubMed
Google Scholar
Jespersen CG, Norgaard M, Borre M: Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2013
Google Scholar